CymaBay Therapeutics Inc (USD)
CBAY
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range6.28 | 6.67
52-Wk Range- | -
Last Close6.51
Mkt Cap (m)448.45
Dividend yield-
ISINUS23257D1037
Volume985,300.00
Exchange VenueNAS

Company Profile

CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.

Key Information
Price/Earning-
Price/Book2.71
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-57.63
Debt/Equity0.01

Documents

Prospectus
en 14/07/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.cymabay.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)0.000.000.0010.000.000.00
Operating Income (m)-24.01-25.90-25.59-21.33-72.51-103.08
Net Income (m)-31.92-15.53-26.67-27.56-72.55-102.81
Basic EPS-2.65-0.82-1.14-0.79-1.25-1.53
Avg. Diluted Shares Outstanding (m)12.0518.9223.4534.9057.8467.03
Balance Sheet
USD201420152016201720182019
Current Assets (m)37.2342.7918.53103.54181.56202.92
Non Current Assets (m)0.250.290.830.705.192.80
Total Assets (m)37.4743.0819.36104.25186.75205.73
Current Liabilities (m)20.466.159.3116.3114.4217.64
Total Liabilities (m)------
Total Equity (m)13.8528.123.9484.95170.42186.35
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-21.11-23.32-23.35-19.63-54.94-97.91
Capital Expenditure (m)-0.10--0.04-0.03-0.53-0.32
Figures are quoted in USD unless stated otherwise
-
No change
$
6.51
Last Price